Best Practice and Research. Clinical Haematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

An Update in Treating Transformed Lymphoma
This article will provide a review of transformed lymphomas with an emphasis on treatment and the nuances of diagnosis and clinical management. Unless otherwise specified, all discussion in this review pertains to transformed follicular lymphoma which is the more common scenario and the subtype with the most robust data. In many cases, this information can be extrapolated and applied to other indolent histologies (i.e. transformed marginal zone lymphoma); however, several other clinical scenarios, such as Richter’s transformation and “double hit” transformations, warrant a distinct discussion and will be reviewed sep...
Source: Best Practice and Research Clinical Haematology - July 25, 2018 Category: Hematology Source Type: research

Immunotherapy in Aggressive B-cell Lymphomas
Publication date: Available online 23 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Caron A. Jacobson, Philippe ArmandAbstractThe idea that the immune system could be co-opted to treat cancer is not new; it has existed for centuries. However, what is new is the advancement of our understanding of how the immune system is regulated and how a tumor evolves to evade an immune response. This knowledge, combined with modern technologies to manipulate the immune system, both pharmacologically and genetically, has led to the realization of immuno-oncology as a new frontier in cancer therapeutics. This r...
Source: Best Practice and Research Clinical Haematology - July 24, 2018 Category: Hematology Source Type: research

Management of relapsed/refractory DLBCL
Publication date: Available online 23 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Clémentine Sarkozy, Laurie H. SehnAbstractDiffuse large B cell lymphoma represents the most common type of non-Hodgkin lymphoma. Although the curability rate is high, around 40% of patients will relapse or exhibit refractory disease. To obtain long-term disease-free survival after relapse, an intensive salvage regimen followed by autologous steam cell transplant remains the standard of care. However, more than 60% of patients will be transplant ineligible, presenting a therapeutic challenge. In this setting, ther...
Source: Best Practice and Research Clinical Haematology - July 24, 2018 Category: Hematology Source Type: research

Burkitt Lymphoma- A Rare But Challenging Lymphoma
Publication date: Available online 23 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Carla Casulo, Jonathan FriedbergAbstractBurkitt lymphoma (BL) is a rare, aggressive subtype of non-Hodgkin lymphoma affecting approximately 1,500 patients per year. Three forms of BL exist (sporadic, endemic, immunodeficiency associated) and the endemic form was first discovered as being driven by the Epstein Barr virus in areas of the world where malaria is prevalent. BL has the characteristic t8;14 cytogenetic translocation that leads to constitutive activation of the MYC gene, which drives BL cell division. The...
Source: Best Practice and Research Clinical Haematology - July 24, 2018 Category: Hematology Source Type: research

Improving Outcomes in Primary CNS Lymphoma
Publication date: Available online 21 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Maya S. Graham, Lisa M. DeAngelisAbstractPrimary central nervous system lymphoma (PCNSL) is an aggressive disease with previously poor prognosis. The advent of high-dose methotrexate-based induction regimens as well as use of consolidation therapy has greatly improved this prognosis in recent decades, but durable remission still eludes half of patients. In this review, we summarize the progress made in the treatment of PCNSL as well as the challenges that remain, with a focus on defining optimal induction and cons...
Source: Best Practice and Research Clinical Haematology - July 21, 2018 Category: Hematology Source Type: research

INTERGRATING novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome
Publication date: Available online 18 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): H. Miles Prince, Christiane QuerfeldAbstractNovel systemic therapies are generally prescribed to patients with advanced-stage disease or those with early-stage disease refractory to skin-directed therapies. In general, systemic chemotherapy should be reserved for patients who fail to respond to biological agents. Such biological agents include interferon alfa, bexarotene, histone deacetylase inhibitors (vorinostat, romidepsin), brentuximab vedotin and mogamulizumab. Extracorporeal photopheresis is particularly eff...
Source: Best Practice and Research Clinical Haematology - July 18, 2018 Category: Hematology Source Type: research

Peripheral T-cell lymphoma – are we making progress?
Publication date: Available online 17 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Niloufer Khan, Neval Ozkaya, Alison Moskowitz, Ahmet Dogan, Steven HorwitzAbstract:Peripheral T cell lymphoma (PTCL) is a rare subtype of non-Hodgkin lymphoma. PTCLs are heterogeneous in terms of biology, but generally have more aggressive features and poorer outcomes than aggressive B-cell lymphomas when treated with combination chemotherapy. While the best long-term results are still seen with intensive chemotherapeutic approaches, significant progress has been made with molecular profiling identifying genetic d...
Source: Best Practice and Research Clinical Haematology - July 18, 2018 Category: Hematology Source Type: research

Successful Role of Radiation Therapy: Account for Every single Gray and Make Every single Gray count.
Publication date: Available online 17 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Bouthaina Shbib DabajaABSTRACTCombined-modality treatment involving immuno-chemotherapy with or without radiation has become the mainstay of treatment for aggressive lymphomas such as diffuse large B-cell lymphoma (DLBCL). Long-term goals in the treatment of DLBCL are to keep improving the therapeutic ratio and to extend survival; these goals have been accomplished largely by (a) gaining insight into disease biology and developing biologically based criteria to guide choice of therapy, (b) avoiding unnecessarily l...
Source: Best Practice and Research Clinical Haematology - July 18, 2018 Category: Hematology Source Type: research

Optimal management of the young patient CLL patient
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): John N. Allan, Richard R. FurmanAbstractThe emergence of targeted therapy for patients with chronic lymphocytic leukemia (CLL) has permanently altered the therapeutic landscape. In both upfront and relapsed settings, safe and effective oral kinase inhibitors are available which rival the responses and durability seen with standard chemo immunotherapy regimens. In 2016, ibrutinib was granted Federal Drug Administration approval for first-line therapy in patients with CLL. While its role as initial therapy for olde...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Index
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Novel therapies for relapsed/refractory mantle cell lymphoma
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Puja C. Arora, Craig A. PortellAbstractMantle cell lymphoma is an aggressive Non-Hodgkin's lymphoma that is considered incurable with standard therapies. Most patients treated with frontline immunochemotherapy relapse within a few years and do not usually respond to salvage chemotherapy. Persistent activation of the B-cell receptor pathway is critical to the pathogenesis of mantle cell lymphoma. Inhibition of Bruton's tyrosine kinase, an essential B-cell receptor pathway component with ibrutinib has shown clinica...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

What is the optimal initial management of the older MCL patient?
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Johanna C. Kluin-Nelemans, Jeanette K. DoorduijnAbstractThe current first line treatment of a patient with mantle cell lymphoma (MCL) is often considered as too toxic for elderly patients. The elderly, however, comprise the majority of the patients with MCL. The results of several recent studies have shown that the outcome of this patient group is not as dismal as in the past. Indeed, if patients are not considered frail, and can tolerate rituximab and moderate intensive chemotherapy such as R-CHOP followed by ri...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

What is the optimal initial management of the younger mantle cell lymphoma patient?
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Rory McCulloch, Simon RuleAbstractThe last 20 years has seen considerable advances made in the management of younger patients with mantle cell lymphoma. The use of high dose cytarabine and rituximab in induction therapy, usually followed by autologous stem cell transplant consolidation, has become established practice and the median overall survival now exceeds 10 years. However, this high intensity upfront approach is not necessarily appropriate for all newly diagnosed patients. A minority exhibit disease that b...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

Indolent lymphomas
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Brad Kahl (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research